Dr. Reddy’s shares spike after favourable generic drug ruling

Shares of Indian drugmaker Dr. Reddy’s Laboratories Ltd jumped nearly 9 percent on Wednesday, their sharpest intraday gain in a year, after a U.S. court allowed the company to sell a copycat version of Indivior Plc’s opioid treatment Suboxone Film.

The U.S. Court of Appeals for the Federal Circuit lifted a preliminary injunction that blocked Dr. Reddy’s from selling the generic, saying a lower court judge erred in granting the request. Shares of Indivior tanked about 47 percent on Tuesday, in a record single-day fall.

“As a result of today’s ruling, Dr. Reddy’s will resume its launch activities as soon as permitted,” the Hyderabad-based generic drugmaker said late on Tuesday.

Investors welcomed the news, with shares of Dr. Reddy’s reaching their highest in nearly two months – 2,655 rupees.

Close to 2.5 million shares had changed hands by 0437 GMT, more than triple the 30-day average of about 788,000 shares.

The stock was the top percentage gainer on the NSE index, which was down 0.7 percent, and helped the Nifty pharma index rise by 1.3 percent.

Jefferies analysts said they consider the ruling to be near-term positive, and one that allows the company to immediately re-launch the product, but still at-risk.

Nomura analysts said they believe DR. Reddy’s is likely to be compensated in due course for the preliminary injunction, but await clarity whether the compensation could be higher than $72 million.

  • Related Posts

    • Pharma
    • July 24, 2025
    • 180 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 269 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra